Emetine compounds for treatment and prevention of flavivirus infection
The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as dengue virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as dengue virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such dengue virus infections.
1. A method for treating or delaying the onset of dengue virus infection in a human or non-human animal subject, said method comprising administering an effective amount of cephaeline, cephaeline isoamyl ether, cephaeline ethyl ether, or a pharmaceutically acceptable salt of any of the foregoing, to the human or non-human animal subject in need thereof.
2. The method of claim 1 , wherein the cephaeline or pharmaceutically acceptable salt thereof is administered to the subject.
3. The method of claim 1 , wherein cephaeline isoamyl ether, cephaeline ethyl ether, or a pharmaceutically acceptable salt of any of the foregoing is administered to the subject.
4. The method of claim 1 , wherein the subject has the dengue virus infection at the time of said administering, and the cephaeline, cephaeline isoamyl ether, cephaeline ethyl ether, or pharmaceutically acceptable salt of any of the foregoing is administered as therapy.
5. The method of claim 4 , further comprising, prior to said administering, identifying the subject as having the dengue virus infection.
6. The method of claim 5 , wherein said identifying comprises assaying a biological sample obtained from the subject for the presence of dengue virus nucleic acids or dengue virus proteins.
7. The method of claim 6 , wherein said assaying comprises use of reverse transcriptase-polymerase chain reaction (RT-PCR), immunological assay, or Plaque-reduction neutralization testing (PRNT).
8. The method of claim 1 , wherein the subject does not have the dengue virus infection at the time of said administering, and the cephaeline, cephaeline isoamyl ether, cephaeline ethyl ether, or pharmaceutically acceptable salt of any of the foregoing is administered to delay onset of the dengue virus infection.
9. The method of claim 1 , wherein the cephaeline, cephaeline isoamyl ether, cephaeline ethyl ether, or pharmaceutically acceptable salt of any of the foregoing is administered orally, nasally, rectally, parenterally, subcutaneously, intramuscularly, or intravascularly.
10. The method of claim 1 , further comprising administering an additional agent for treating or delaying the onset of dengue virus infection, or a symptom thereof, in the same formulation as the cephaeline, cephaeline isoamyl ether, cephaeline ethyl ether, or pharmaceutically acceptable salt of any of the foregoing, or in a separate formulation before, during, or after administration of the cephaeline, cephaeline isoamyl ether, cephaeline ethyl ether, or pharmaceutically acceptable salt of any of the foregoing.
11. A method for inhibiting dengue virus infection in human or non-human animal cells in vitro or in vivo, said method comprising contacting an effective amount of cephaeline, cephaeline isoamyl ether, cephaeline ethyl ether, or a pharmaceutically acceptable salt thereof to a human or non-human animal cell in vitro or in vivo before or after exposure of the cell to dengue virus.
12. The method of claim 11 , wherein an effective amount of cephaeline or pharmaceutically acceptable salt thereof is contacted to the cell.
13. The method of claim 11 , wherein an effective amount of cephaeline isoamyl ether, cephaeline ethyl ether, or a pharmaceutically acceptable salt of any of the foregoing is contacted to the cell.
14. The method of claim 11 , wherein the cell is a human cell.
15. The method of claim 11 , wherein said contacting to the cell is in vivo.
16. The method of claim 11 , wherein said contacting to the cell is in vitro.
17. The method of claim 1 , wherein the dengue virus is serotype 1, 2, 3, or 4.
18. The method of claim 11 , wherein the dengue virus is serotype 1, 2, 3, or 4.
19. The method of claim 1 , wherein the subject is human.